Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

High Starting Infliximab Doses Recommended for Hidradenitis Suppurativa

Publish date:: July 15, 2019

Key clinical point: For hidradenitis suppurativa, the starting dose of infliximab should be higher than the 5 mg/kg recommended for psoriasis.

Major finding: On a 7.5 mg/kg starting dose of infliximab, average pain scores fell from 5.65 to 1.34 within 4 weeks.

Data Source: A retrospective chart review.

Disclosures: The authors report no potential conflicts of interest.

Citation:

77th Annual Meeting of the Society for Investigative Dermatology

This Week's Must Reads

Osteoporosis prevalence in PsA similar to general population,

Swedish registry study finds atopic dermatitis significantly associated with autoimmune diseases,

More severe AD correlates with worse sleep health and attention problems in children,

Shortcomings identified in study of acne videos on TikTok,

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Must Reads in Medical Dermatology

New lupus classification criteria perform well in children, young adults,

Phone outreach intervention feasible to reduce SLE readmissions,

Age, smoking among leading cancer risk factors for SLE patients,

Cachexia affects more than half of lupus patients,

Ixekizumab deemed effective for pityriasis rubra pilaris,